Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
|Articles|March 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 3
- Volume 4
- Issue 3
ASIM Joins Coalition in Effort to Bring Tobacco Industry Under FDA Control
WASHINGTON--The American Society of Internal Medicine (ASIM) joined the Coalition on Smoking OR Health in its effort to create FDA oversight of the tobacco industry. ASIM's policy on tobacco supports stronger cigarette labels,
Advertisement
WASHINGTON--The American Society of Internal Medicine (ASIM) joinedthe Coalition on Smoking OR Health in its effort to create FDAoversight of the tobacco industry. ASIM's policy on tobacco supportsstronger cigarette labels, increasing the legal age to buy tobaccoproducts to 21, and a ban on tobacco advertising or at least eliminationof its tax deductibility.
Articles in this issue
over 31 years ago
Selecting a Support Group for Patients With Prostate Carcinomaover 31 years ago
Antman Provides Outlook on Use of High-Dose Chemoover 31 years ago
Radiofrequency Ablation of Brain Tumors New Optionover 31 years ago
Oncologist Enthusiastic About Capitated Planover 31 years ago
Varmins Chooses New Director for NIH Office of Alternative Medicineover 31 years ago
'Visible Man' Hits the Internet, Radiologists Get the First Lookover 31 years ago
Ultrafast Full-Body MRI Eases Procedure in Claustrophobics, KidsAdvertisement
Related to this article
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Rutika Mehta, MD, MPH, discussed biomarker testing, PD-L1–low treatment, FLOT dosing, early referral, and ctDNA in gastroesophageal cancer.
Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma
3
Scaling Low-Dose Radiation Therapy for Osteoarthritis Across a Network
4
Surgery Correlates With Better Survival Vs SABR in Early-Stage NSCLC
5